Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Population pharmacokinetic model for a novel oral hypoglycemic formed in vivo: comparing the use of active metabolite data alone versus using data of upstream and downstream metabolites.

Kastrissios H, Walker JR, Carrothers TJ, Kshirsagar S, Khariton T, Habtemariam B, Mager DE, Rohatagi S.

J Clin Pharmacol. 2012 Mar;52(3):404-15. doi: 10.1177/0091270010396373. Epub 2011 Mar 21.

PMID:
21422240
2.

Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.

Dang Q, Liu Y, Cashion DK, Kasibhatla SR, Jiang T, Taplin F, Jacintho JD, Li H, Sun Z, Fan Y, DaRe J, Tian F, Li W, Gibson T, Lemus R, van Poelje PD, Potter SC, Erion MD.

J Med Chem. 2011 Jan 13;54(1):153-65. doi: 10.1021/jm101035x. Epub 2010 Dec 2.

PMID:
21126019
3.

Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency.

Ott P, Ranek L, Young MA.

Eur J Clin Pharmacol. 1998 Sep;54(7):567-71.

PMID:
9832300
4.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
5.

Prediction of prasugrel active metabolite concentrations from 2 downstream inactive metabolite concentrations using multilinear regression analysis.

Ernest CS 2nd, Heathman MA, Wrishko RE.

J Clin Pharmacol. 2009 Aug;49(8):973-83. doi: 10.1177/0091270009340416.

PMID:
19602721
6.

Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.

Lal R, Sukbuntherng J, Luo W, Chen D, Blumenthal R, Ho J, Cundy KC.

Clin Ther. 2012 Jan;34(1):201-13. doi: 10.1016/j.clinthera.2011.12.004. Epub 2011 Dec 28.

PMID:
22206794
7.

A prodrug approach towards the development of tricyclic-based FBPase inhibitors.

Tsukada T, Tamaki K, Tanaka J, Takagi T, Yoshida T, Okuno A, Shiiki T, Takahashi M, Nishi T.

Bioorg Med Chem Lett. 2010 May 1;20(9):2938-41. doi: 10.1016/j.bmcl.2010.03.017. Epub 2010 Mar 7.

PMID:
20359891
8.

Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.

Joerger M, Huitema AD, Meenhorst PL, Schellens JH, Beijnen JH.

Cancer Chemother Pharmacol. 2005 May;55(5):488-96. Epub 2005 Feb 23.

PMID:
15726371
9.

Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38.

Wrishko RE, Ernest CS 2nd, Small DS, Li YG, Weerakkody GJ, Riesmeyer JR, Macias WL, Rohatagi S, Salazar DE, Antman EM, Wiviott SD, Braunwald E, Ni L.

J Clin Pharmacol. 2009 Aug;49(8):984-98. doi: 10.1177/0091270009337942. Epub 2009 Jun 22.

PMID:
19546250
10.

Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study.

Loi CM, Randinitis EJ, Vassos AB, Kazierad DJ, Koup JR, Sedman AJ.

J Clin Pharmacol. 1997 Dec;37(12):1114-20.

PMID:
9506006
11.

Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites.

Loi CM, Alvey CW, Randinitis EJ, Abel R, Young MA, Koup JR.

J Clin Pharmacol. 1997 Nov;37(11):1038-47.

PMID:
9505997
12.

Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.

de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA.

J Pharmacokinet Pharmacodyn. 2009 Dec;36(6):541-64. doi: 10.1007/s10928-009-9136-6. Epub 2009 Nov 11.

13.

The influence of sparse data sampling on population pharmacokinetics: a post hoc analysis of a pharmacokinetic study of morphine in healthy volunteers.

Ariano RE, Duke PC, Sitar DS.

Clin Ther. 2012 Mar;34(3):668-76. doi: 10.1016/j.clinthera.2012.01.023. Epub 2012 Feb 28.

PMID:
22381713
15.

An unusual metabolic pathway of sipoglitazar, a novel antidiabetic agent: cytochrome P450-catalyzed oxidation of sipoglitazar acyl glucuronide.

Nishihara M, Sudo M, Kawaguchi N, Takahashi J, Kiyota Y, Kondo T, Asahi S.

Drug Metab Dispos. 2012 Feb;40(2):249-58. doi: 10.1124/dmd.111.040105. Epub 2011 Oct 25.

16.

The design and synthesis of thrombin inhibitors: the introduction of in vivo efficacy and oral bioavailability into benzthiazolylalanine inhibitors.

Hayler J, Kane PD, LeGrand D, Lugrin F, Menear K, Price R, Allen M, Cockcroft X, Ambler J, Butler K, Dunnet K, Mitchelson A, Talbot M, Tweed M, Wills N.

Bioorg Med Chem Lett. 2000 Jul 17;10(14):1567-70.

PMID:
10915052
17.

Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958.

Ishizuka H, Yoshiba S, Yoshihara K, Okabe H.

J Clin Pharmacol. 2011 Feb;51(2):243-51. doi: 10.1177/0091270010361914. Epub 2010 Mar 2.

PMID:
20197485
18.

Predictive population pharmacokinetic/pharmacodynamic model for a novel COX-2 inhibitor.

Rohatagi S, Kastrissios H, Gao Y, Zhang N, Xu J, Moberly J, Wada R, Yoshihara K, Takahashi M, Truitt K, Salazar D.

J Clin Pharmacol. 2007 Mar;47(3):358-70.

PMID:
17322148
19.

Sulfonylureido thiazoles as fructose-1,6-bisphosphatase inhibitors for the treatment of type-2 diabetes.

Kitas E, Mohr P, Kuhn B, Hebeisen P, Wessel HP, Haap W, Ruf A, Benz J, Joseph C, Huber W, Sanchez RA, Paehler A, Benardeau A, Gubler M, Schott B, Tozzo E.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):594-9. doi: 10.1016/j.bmcl.2009.11.093. Epub 2009 Nov 22.

PMID:
19969452
20.

Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.

Reddy KA, Lohray BB, Bhushan V, Reddy AS, Rao Mamidi NV, Reddy PP, Saibaba V, Reddy NJ, Suryaprakash A, Misra P, Vikramadithyan RK, Rajagopalan R.

J Med Chem. 1999 Aug 26;42(17):3265-78.

PMID:
10464013

Supplemental Content

Support Center